{
    "Trade/Device Name(s)": [
        "Alere Afinion\u2122 HbA1c",
        "Alere Afinion\u2122 ACR",
        "Afinion\u2122 2"
    ],
    "Submitter Information": "Abbott Rapid Diagnostics",
    "510(k) Number": "K171650",
    "Predicate Device Reference 510(k) Number(s)": [
        "K151809",
        "K050574",
        "K072409",
        "K110056"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "JFY",
        "JQT"
    ],
    "Summary Letter Date": "June 2, 2017",
    "Summary Letter Received Date": "June 5, 2017",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7470",
        "21 CFR 862.1225",
        "21 CFR 862.2400"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "hematology",
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c",
        "Albumin",
        "Creatinine",
        "Albumin/Creatinine Ratio (ACR)"
    ],
    "Specimen Type(s)": [
        "Whole blood",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Afinion\u2122 2 analyzer"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Analyzer",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Alere Afinion\u2122 HbA1c and ACR assays on Afinion\u2122 2 analyzer for point-of-care quantitative testing of HbA1c in blood and albumin, creatinine, and ACR in urine.",
    "Indications for Use Summary": "Afinion\u2122 2 analyzer performs quantitative HbA1c testing in whole blood for diabetes management and quantitative albumin, creatinine, and ACR testing in urine to aid early nephropathy diagnosis.",
    "fda_folder": "Hematology"
}